[1] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA:a Cancer J Clin, 2018, 68(6):394-424.
[2] FERLAY J, COLOMBET M, SOERJOMATARAM I, et al. Estimating the global cancer incidence and mortality in 2018:GLOBOCAN sources and methods[J]. Int J Cancer, 2019, 144(8):1941-1953.
[3] KOYFMAN S A, ISMAILA N, CROOK D, et al. Management of the neck in squamous cell carcinoma of the oral cavity and oropharynx:ASCO clinical practice guideline[J]. J Clin Oncol, 2019, 37(20):1753-1774.
[4] DHAWAN A, SCOTT J G, HARRIS A L, et al. Pan-cancer characterisation of microRNA across cancer hallmarks reveals microRNA-mediated downregulation of tumour suppressors[J]. Nat Commun, 2018, 9(1):5228.
[5] FILIPOWICZ W, BHATTACHARYYA S N, SONENBERG N. Mechanisms of post-transcriptional regulation by microRNAs:are the answers in sight-[J]. Nat Rev Genet, 2008, 9(2):102-114.
[6] EBERT M S, SHARP P A. Roles for microRNAs in conferring robustness to biological processes[J]. Cell, 2012, 149(3):515-524.
[7] JONAS S, IZAURRALDE E. Towards a molecular understanding of microRNA-mediated gene silencing[J]. Nat Rev Genet, 2015, 16(7):421-433.
[8] DJURANOVIC S, NAHVI A, GREEN R. miRNA-mediated gene silencing by translational repression followed by mRNA deadenylation and decay[J]. Science, 2012, 336(6078):237-240.
[9] JONAS S, IZAURRALDE E. Towards a molecular understanding of microRNA-mediated gene silencing[J]. Nat Rev Genet, 2015, 16(7):421-433.
[10] VANNINI I, FANINI F, FABBRI M. Emerging roles of microRNAs in cancer[J]. Curv Opin Genet Dev, 2018, 18:128-133.
[11] BARBATO S, SOLAINI G, FABBRI M. MicroRNAs in oncogenesis and tumor suppression[J]. 2017, 333:229-268.
[12] LU J, GETZ G, MISKA E A, et al. MicroRNA expression profiles classify human cancers[J]. Nature, 2005, 435(7043):834-838.
[13] TRAN N, MCLEAN T, ZHANG X Y, et al. MicroRNA expression profiles in head and neck cancer cell lines[J]. Biochem Biophys Res Commun, 2007, 358(1):12-17.
[14] WONG T S, LIU X B, WONG B Y, et al. Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue[J]. Clin Cancer Res, 2008, 14(9):2588-2592.
[15] LU Y C, CHEN Y J, WANG H M, et al. Oncogenic function and early detection potential of miRNA-10b in oral cancer as identified by microRNA profiling[J]. Cancer Prev Res (Phila), 2012, 5(4):665-674.
[16] MANIKANDAN M, DEVA MAGENDHRA RAO A K, ARUNKUMAR G, et al. Oral squamous cell carcinoma:microRNA expression profiling and integrative analyses for elucidation of tumourigenesis mechanism[J]. Mol Cancer, 2016, 15:28.
[17] 杨青, 潘悦, 肖桂山. miR-23b对口腔癌转移影响[J]. 大连理工大学学报, 2020, 60(1):10-14.
[18] 常凯, 高继萍, 宋晓娜, 等. miR-34c在口腔鳞状细胞癌的表达及对Tca8113细胞生物学行为的影响[J]. 中国比较医学杂志, 2018, 28(11):15-20.
[19] 王丽萍, 郭雪琪, 闫勇勇, 等. miR-146a在口腔鳞癌组织及细胞中的表达及功能研究[J]. 口腔医学研究, 2017, 33(11):1204-1208.
[20] 翁军权, 范海东, 许力强, 等. MiR-520b调控Wnt/β-catenin信号通路促进舌鳞状细胞癌侵袭转移[J]. 中华口腔医学研究杂志:电子版, 2020, 14(3):155-163.
[21] MIKE GORENCHTEIN R T. Dysregulation of microRNAs across oral squamous cell carcinoma fields in non-smokers[J]. J Interdiscipl Med Dent Sci, 2014, 2(4):131.
[22] SHIAH S G, HSIAO J R, CHANG W M, et al. Downregulated miR329 and miR410 promote the proliferation and invasion of oral squamous cell carcinoma by targeting Wnt-7b[J]. Cancer Res, 2014, 74(24):7560-7572.
[23] NETWORK C G A. Comprehensive genomic characterization of head and neck squamous cell carcinomas[J]. Nature, 2015, 517(7536):576-582.
[24] BOZINOVIC K, SABOL I, DEDIOL E, et al. Genome-wide miRNA profiling reinforces the importance of miR-9 in human papillomavirus associated oral and oropharyngeal head and neck cancer[J]. Sci Rep, 2019, 9(1):2306.
[25] GHOSH R D, PATTATHEYIL A, ROYCHOUDHURY S. Functional landscape of dysregulated MicroRNAs in oral squamous cell carcinoma:clinical implications[J]. Front Oncol, 2020, 10:619. DOI:10.3389/fonc.2020.00619.
[26] BRITO J A, GOMES C C, GUIMAR-ES A L, et al. Relationship between microRNA expression levels and histopathological features of dysplasia in oral leukoplakia[J]. J Oral Pathol Med, 2014, 43(3):211-216.
[27] KINOSHITA T, NOHATA N, HANAZAWA T, et al. Tumour-suppressive microRNA-29s inhibit cancer cell migration and invasion by targeting laminin-integrin signalling in head and neck squamous cell carcinoma[J]. Br J Cancer, 2013, 109(10):2636.
[28] TACHIBANA H, SHO R, TAKEDA Y, et al. Circulating miR-223 in oral cancer:its potential as a novel diagnostic biomarker and therapeutic target[J]. PLoS One, 2016, 11(7):e0159693.
[29] SUN G, CAO Y, WANG P, et al. miR-200b-3p in plasma is a potential diagnostic biomarker in oral squamous cell carcinoma[J]. Biomarkers, 2018, 23(2):137-141.
[30] CHANG Y A, WENG S L, YANG S F, et al. A three-microRNA signature as a potential biomarker for the early detection of oral cancer[J]. Int J Mol Sci, 2018, 19(3):758.
[31] QIAO B, CAI J H, KING-YIN LAM A, et al. MicroRNA-542-3p inhibits oral squamous cell carcinoma progression by inhibiting ILK/TGF-β1/Smad2/3 signaling[J]. Oncotarget, 2017, 8(41):70761-70776.
[32] ZHANG B, LI Y, HOU D, et al. MicroRNA-375 inhibits growth and enhances radiosensitivity in oral squamous cell carcinoma by targeting insulin like growth factor 1 receptor[J]. Cell Physiol Biochem, 2017, 42(5):2105-2117.
[33] KOSHIZUKA K, HANAZAWA T, KIKKAWA N, et al. Antitumor miR-150-5p and miR-150-3p inhibit cancer cell aggressiveness by targeting SPOCK1 in head and neck squamous cell carcinoma[J]. Auris Nasus Larynx, 2018, 45(4):854-865.
[34] LIN F, YAO L, XIAO J, et al. MiR-206 functions as a tumor suppressor and directly targets K-Ras in human oral squamous cell carcinoma[J]. Onco Targets Ther, 2014, 7:1583-1591.
[35] KAWAHARA K, NAKAYAMA H, NAGATA M, et al. A low dicer expression is associated with resistance to 5-FU-based chemo-radiotherapy and a shorter overall survival in patients with oral squamous cell carcinoma[J]. J Oral Pathol Med, 2014, 43(5):350-356.
[36] SHIIBA M, SHINOZUKA K, SAITO K, et al. MicroRNA-125b regulates proliferation and radioresistance of oral squamous cell carcinoma[J]. Br J Cancer, 2013, 108(9):1817-1821.
[37] GHOSH R D, GHUWALEWALA S, DAS P, et al. MicroRNA profiling of cisplatin-resistant oral squamous cell carcinoma cell lines enriched with cancer-stem-cell-like and epithelial-mesenchymal transition-type features[J]. Sci Rep, 2016, 6:23932.
[38] ZHOU X, REN Y, LIU A, et al. WP1066 sensitizes oral squamous cell carcinoma cells to cisplatin by targeting STAT3/miR-21 axis[J]. Sci Rep, 2014, 4:7461.
[39] SUH Y E, RAULF N, GÄKEN J, et al. MicroRNA-196a promotes an oncogenic effect in head and neck cancer cells by suppressing annexin A1 and enhancing radioresistance[J]. Int J Cancer, 2015, 137(5):1021-1034.
[40] CHEN D, YAN W, LIU Z, et al. Downregulation of miR-221 enhances the sensitivity of human oral squamous cell carcinoma cells to Adriamycin through upregulation of TIMP3 expression[J]. Biomed Pharmacother, 2016, 77:72-78.
[41] YU Z W, ZHONG L P, JI T, et al. MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines[J]. Oral Oncol, 2010, 46(4):317-322.
[42] LIN J, LIN Y, FAN L, et al. miR-203 inhibits cell proliferation and promotes cisplatin induced cell death in tongue squamous cancer[J]. Biochem Biophys Res Commun, 2016, 473(2):382-387.
[43] MOLLAEI H, SAFARALIZADEH R, ROSTAMI Z. MicroRNA replacement therapy in cancer[J]. J Cell Physiol, 2019, 234(8):12369-12384.
[44] LIU C J, LIN J S, CHENG H W, et al. Plasma miR-187* is a potential biomarker for oral carcinoma[J]. Clin Oral Invest, 2017, 21(4):1131-1138.
[45] LU Z, HE Q, LIANG J, et al. miR-31-5p is a potential circulating biomarker and therapeutic target for oral cancer[J]. Mol Ther Nucleic Acids, 2019, 16:471-480.
[46] RUPAIMOOLE R, SLACK F J. MicroRNA therapeutics:towards a new era for the management of cancer and other diseases[J]. Nat Rev Drug Discov, 2017, 16(3):203-222.
[47] KAMERKAR S, LEBLEU V S, SUGIMOTO H, et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer[J]. Nature, 2017, 546(7659):498-503.
[48] BOUCHIE A. First microRNA mimic enters clinic[J]. Nat Biotechnol, 2013, 31(7):577. |
